Clinical trial
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment…
NCT00400478 · Arbeitsgemeinschaft medikamentoese Tumortherapie, Other · Completed
Key facts
| NCT number | NCT00400478 |
|---|---|
| Title | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 |
| Official title | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 |
| Lead sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diffuse Large B-Cell Lymphoma (DLBCL), Follicular NHL Grade 3b |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 683 |
| Start date | Jan 1, 2006 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Nov 17, 2006 |
| Last update posted | May 26, 2016 |
| Countries | Australia, Austria, Bosnia and Herzegovina, Brazil, Bulgaria, China, Croatia, Czechia, Estonia, Hong Kong, Israel, Latvia and 14 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: